VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.


Journal Article

The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.

Full Text

Duke Authors

Cited Authors

  • DeVore, AD; Milano, CA; Rogers, JG

Published Date

  • November 2014

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 603 - 605

PubMed ID

  • 25512902

Pubmed Central ID

  • 25512902

International Standard Serial Number (ISSN)

  • 2225-319X

Digital Object Identifier (DOI)

  • 10.3978/j.issn.2225-319X.2014.08.22


  • eng

Conference Location

  • China